Cargando…
Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Currently no approved treatment exists for fibrodysplasia ossificans progressiva (FOP) patients, and disease progression results in severe restriction of joint function and premature mortality. LDN-193189 has been demonstrated to be efficacious in a mouse FOP disease model after oral administration....
Autores principales: | Padilha, Elias C., Wang, Jianyao, Kerns, Ed, Lee, Arthur, Huang, Wenwei, Jiang, Jian-kang, McKew, John, Mutlib, Abdul, Peccinini, Rosangela G., Yu, Paul B., Sanderson, Philip, Xu, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491728/ https://www.ncbi.nlm.nih.gov/pubmed/31068801 http://dx.doi.org/10.3389/fphar.2019.00234 |
Ejemplares similares
-
Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)
por: Hsiao, Edward C., et al.
Publicado: (2018) -
Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome
por: Pignolo, Robert J., et al.
Publicado: (2020) -
PSAT180 Fibrodysplasia Ossificans Progressiva (FOP) A Case Series
por: Almonaei, Khulod, et al.
Publicado: (2022) -
Clinical, evolution and therapeutical considerations upon a case of fibrodysplasia ossificans progressiva (FOP)
por: Rogoveanu, O, et al.
Publicado: (2013) -
Fibrodysplasia ossificans progressiva
por: Smit, Chané, et al.
Publicado: (2023)